Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05168735 · ClinicalTrials.gov registry record · Phase 1

Ketamine + Mindfulness for Depression

A Phase 1 study of Depression, Unipolar, sponsored by Rebecca Price.

Completed
Registry status
Phase 1
Development phase
43
Enrollment target
1
Study location

NCT05168735: Completed Phase 1 study of Depression, Unipolar, sponsored by Rebecca Price.

NCT05168735 is a Phase 1 study of Depression, Unipolar that has completed, run by Rebecca Price. The registered enrollment target is 43 participants, below the 317-participant average among 3 other Depression, Unipolar trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05168735, a Phase 1 study of Depression, Unipolar, has completed, sponsored by Rebecca Price.

COMPLETED
Registry status
Phase 1
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.

Primary Outcome

Clinician-rated depression (range: 0-60; higher scores = worse outcome)

Conditions Studied

Interventions

  • DRUG Intravenous Ketamine
  • BEHAVIORAL Brief Mindfulness Exercises
  • BEHAVIORAL Academic Exercises

Study Locations (1)

Pennsylvania

  • Western Psychiatric Institute and Clinic - Pittsburgh

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2022-02-01
Est. Completion 2023-09-01
Phase Phase 1
Rebecca Price

7 total trials

What the finished NCT05168735 record still lists

NCT05168735 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 317-participant average among 3 other Depression, Unipolar trials with a reported enrollment target (86% lower).

The record links to 1 condition, with Depression, Unipolar appearing as the primary indexed condition, and to 3 interventions - of which Intravenous Ketamine is the first listed.

NCT05168735 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05168735 about?

NCT05168735 is a clinical study titled "Ketamine + Mindfulness for Depression". In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the c...

What is the current status of trial NCT05168735?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-02-01. Estimated completion is 2023-09-01.

What conditions does trial NCT05168735 study?

This clinical trial studies the following conditions: Depression, Unipolar.

What interventions are being tested in trial NCT05168735?

The interventions under investigation include: Intravenous Ketamine (DRUG), Brief Mindfulness Exercises (BEHAVIORAL), Academic Exercises (BEHAVIORAL).

Who is sponsoring clinical trial NCT05168735?

This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05168735 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression, Unipolar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05168735, the US trial registry maintained by the National Library of Medicine. NCT05168735 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.